Lonafarnib
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Zokinvy | — | 2022-07-18 | europa.eu ↗ |
| Approved | US (FDA) | ZOKINVY | — | 2020-11-20 | fda.gov ↗ |
Trials 37
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-28 | AnGes, Inc. | Regulatory 早老症（HGPS及びPL）治療薬lonafarnib（米国販売名：Zokinvy）の希少疾病医薬品指定に関するお知らせ anges.co.jp ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-04 | Zydus Lifesciences Limited | Sentynl Therapeutics announces global acquisition of Zokinvy® (Lonafarnib) for treatment of Hutchinson-Gilford Progeria Syndrome from Eiger Biopharmaceuticals zyduslife.com ↗ |
| 2024-05-03 | Sentynl Therapeutics, Inc. | Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals sentynl.com ↗ |
| 2023-03-28 | AnGes, Inc. | 早老症（HGPS及びPL）治療薬lonafarnib（米国販売名：Zokinvy）の希少疾病医薬品指定に関するお知らせ anges.co.jp ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 45 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lonafarnib | “A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in...” PMID 18058098 ↗ Dec 200732“This is an open-label clinical trial treating 30 adult patients with chronic delta hepatitis with peginterferon lambda and lonafarnib boosted with ritonavir for 48 weeks.” NCT05953545 ↗ “A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.” PMID 19433965 ↗ Jun 2009 |
| Known as | LNF | “We propose to treat 21 adult patients with chronic delta hepatitis using the combination of the farnesyltransferase inhibitor (FTI) lonafarnib (LNF) and the protease inhibitor...” NCT02511431 ↗ |
| Known as | SARASAR | “Docetaxel (Taxotere®); lonafarnib (SCH 066336, Sarasar®)” NCT00539968 ↗1“Lonafarnib (SARASAR)” NCT00050336 ↗ |
| Known as | SCH 066336 | “Docetaxel (Taxotere®); lonafarnib (SCH 066336, Sarasar®)” NCT00539968 ↗ |
| Known as | SCH 66336 | “The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced...” NCT00034684 ↗11“The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with intravenous...” NCT00040547 ↗ “A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.” PMID 19433965 ↗ Jun 2009 “Phase I Study of Lonafarnib (SCH66336) in Combination With Herceptin Plus Paclitaxel in HER 2 NEU Overexpressing Breast Cancer” NCT00068757 ↗ “Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas” NCT00083096 ↗ “Lonafarnib/SCH 66336” NCT00050336 ↗ |
| Known as | SCH 663366 | “A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in...” PMID 18058098 ↗ Dec 2007 |
| Known as | SCH 6636 | “Farnesyl Protein Transferase Inhibitor (Lonafarnib/SCH 6636)” NCT00073450 ↗ |
| Known as | Zokinvy | “FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.” PMID 36507973 ↗ Dec 2022 |
| Action | Inhibit | “the farnesyl transferase inhibitor SCH66336” PMID 15911238 ↗ May 2005 |
| Modality | Small molecule | “SCH66336, A Farnesyltransferase Inhibitor” NCT00038597 ↗ |
| Route | Oral | “Patients receive oral SCH 66336 twice daily for 7-14 days prior to exploratory laparotomy and/or resection of hepatic metastases.” NCT00005030 ↗ |